Beriplex® P/N (Kcentra) + Fresh frozen plasma

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Blood Coagulation Disorders

Conditions

Blood Coagulation Disorders, Acute Major Bleeding

Trial Timeline

Jun 1, 2008 → Nov 1, 2010

NCT ID

NCT00708435

About Beriplex® P/N (Kcentra) + Fresh frozen plasma

Beriplex® P/N (Kcentra) + Fresh frozen plasma is a phase 3 stage product being developed by CSL for Blood Coagulation Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT00708435. Target conditions include Blood Coagulation Disorders, Acute Major Bleeding.

What happened to similar drugs?

7 of 16 similar drugs in Blood Coagulation Disorders were approved

Approved (7) Terminated (6) Active (6)

✅micafungin + voriconazoleAstellas PharmaApproved

✅Bunazosin + Doxazosin + ValsartinEisaiApproved

🔄Metoprolol Succinate + HydrochlorothiazideAstraZenecaPhase 3

✅AliskirenNovartisApproved

✅Aliskiren and HCTZNovartisApproved

🔄Fibrinogen Concentrate (Human) (FCH) + PlaceboCSLPhase 3

❌Trasylol (Aprotinin, BAYA0128) + PlaceboBayerPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (2)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00803101	Phase 3	Completed	Feb 1, 2009	Feb 1, 2013	Reversal of Coagulopathy
NCT00708435	Phase 3	Completed	Jun 1, 2008	Nov 1, 2010	Blood Coagulation Disorders

Competing Products

20 competing products in Blood Coagulation Disorders

See all competitors

Product	Company	Stage	Hype Score
micafungin + voriconazole	Astellas Pharma	Approved	35
Cefiderocol	Shionogi	Phase 2	35
Bunazosin + Doxazosin + Valsartin	Eisai	Approved	43
Pegfilgrastim	Kyowa Kirin	Phase 2	35
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2/3	38
epoetin alfa	Johnson & Johnson	Phase 2	35
Metoprolol Succinate + Hydrochlorothiazide	AstraZeneca	Phase 3	40
AZD6140 + Placebo	AstraZeneca	Phase 1	29
NKTR-118 + moxifloxacin + Placebo	AstraZeneca	Phase 1	29
MEDI-551	AstraZeneca	Phase 1	29
Ecallantide + Cyklokapron(R)	Merck	Phase 2	35
Daptomycin	Merck	Phase 2	35
ecallantide + placebo	Merck	Phase 2	35
MK0859	Merck	Phase 1	29
Ecallantide + Placebo	Merck	Phase 2	27
HSC835	Novartis	Phase 2	35
Aliskiren	Novartis	Approved	35
Aliskiren and HCTZ	Novartis	Approved	43
Aliskiren + Amlodipine + Placebo Aliskiren + Placebo Amlodipine	Novartis	Phase 2	35